Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIIL 284 BS Tablet C and D vs WIF Tablet
NCT02265653Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1999
- Primary completion
- Dec 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of amelubant in chronic obstructive pulmonary disease (COPD) and asthma, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity at 72 hours, Maximum measured concentration at 72 hours and 5 more. Started Nov 1999; status: completed.
02
Drugs
amelubant
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT02265653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265653.